Current therapy of the Lambert-Eaton myasthenic syndrome.
Lundh
H
H
Department of Neurology, Halmstad Hospital, Sweden.
Nilsson
O
O
Rosén
I
I
D000631:Aminopyridines / Q000009:adverse effects / Q000627:therapeutic use; D019791:Guanidine; D006146:Guanidines / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D015624:Lambert-Eaton Myasthenic Syndrome / Q000188:drug therapy / Q000503:physiopathology / Q000628:therapy*; D010277:Parasympathomimetics / Q000627:therapeutic use; D010951:Plasma Exchange
D000631:Aminopyridines; D006146:Guanidines; D007166:Immunosuppressive Agents; D010277:Parasympathomimetics; D019791:Guanidine